Skip to main content

Table 1 Characteristics of the patient

From: Preclinical investigations and first-in-human application of 152Tb-PSMA-617 for PET/CT imaging of prostate cancer

Age59 years
Height186 cm
Body weight90 kg
Cancer typeMetastatic, hormone-refractory, poorly-differentiated prostate adenocarcinoma
Gleason score8 (4 + 4)
MetastasesResidual primary tumor within the prostate bed with bilateral seminal vesicle infiltration and multiple lymph node as well as bone metastases
Stage of the disease (at initial diagnosis)IV
Karnofsky index (at the time of this study)90%
Relevant previous surgeryCytoreductive Da-Vinci assisted robotic prostatovesiculectomy with bilateral regional lymphadenectomy
Other relevant treatmentAndrogen deprivation therapy with NSAA (Bicalutamide) and GnRH analogue (Leuprorelin, Trenantone™)
PET/CT scan (152Tb-PSMA-617)24 Days after PET/CT scan with 68Ga-PSMA-11
  1. NSAA non-steroidal antiandrogen, GnRH gonadotropin-releasing hormone